BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34841680)

  • 1. Comparison of flow cytometry with other modalities in the diagnosis of myelodysplastic syndrome.
    Pembroke JS; Joseph JE; Smith SABC; Parker AJC; Jiang W; Sewell WA
    Int J Lab Hematol; 2022 Apr; 44(2):313-319. PubMed ID: 34841680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56.
    Drexler B; Tzankov A; Martinez M; Baerlocher S; Passweg JR; Dirnhofer S; Tsakiris DA; Dirks J
    Int J Lab Hematol; 2021 Oct; 43(5):1078-1084. PubMed ID: 33709561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube.
    Rajab A; Porwit A
    Cytometry B Clin Cytom; 2015; 88(4):253-60. PubMed ID: 25664445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes.
    Shameli A; Dharmani-Khan P; Auer I; Shabani-Rad MT
    Leuk Res; 2023 Nov; 134():107401. PubMed ID: 37774446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells.
    Ogata K; Sei K; Saft L; Kawahara N; Porta MGD; Chapuis N; Yamamoto Y
    Leuk Res; 2018 Aug; 71():75-81. PubMed ID: 30025279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of multiparametric flow cytometry in diagnosis & prognosis of myelodysplastic syndrome in India.
    Dhingra G; Dass J; Arya V; Gupta N; Saraf A; Langer S; Aggarwal S; Kotwal J; Bhargava M
    Indian J Med Res; 2020 Sep; 152(3):254-262. PubMed ID: 33107485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic significance of flow cytometry scales in diagnostics of myelodysplastic syndromes.
    Davydova YO; Parovichnikova EN; Galtseva IV; Kokhno AV; Dvirnyk VN; Kovrigina AM; Obukhova TN; Kapranov NM; Nikiforova KA; Glinkina SA; Troitskaya VV; Mikhailova EA; Fidarova ZT; Moiseeva TN; Lukina EA; Tsvetaeva NV; Nikulina OF; Kuzmina LA; Savchenko VG
    Cytometry B Clin Cytom; 2021 May; 100(3):312-321. PubMed ID: 33052634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows".
    Tsagarakis NJ; Paterakis G; Papadhimitriou SI; Kritikou-Griva E; Goumakou E; Oudatzis G; Theodorakos I; Vasileiou P
    Int J Lab Hematol; 2019 Aug; 41(4):542-549. PubMed ID: 31102331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using 4-color flow cytometry to identify abnormal myeloid populations.
    Kussick SJ; Wood BL
    Arch Pathol Lab Med; 2003 Sep; 127(9):1140-7. PubMed ID: 12946231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
    van de Loosdrecht AA; Westers TM; Westra AH; Dräger AM; van der Velden VH; Ossenkoppele GJ
    Blood; 2008 Feb; 111(3):1067-77. PubMed ID: 17971483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of flow cytometric immunophenotyping in myelodysplastic syndromes.
    Pagnucco G; Giambanco C; Gervasi F
    Ann N Y Acad Sci; 2006 Nov; 1089():383-94. PubMed ID: 17261782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic application and clinical significance of FCM progress scoring system based on immunophenotyping in CD34+ blasts in myelodysplastic syndromes.
    Xu F; Guo J; Wu LY; He Q; Zhang Z; Chang CK; Li X
    Cytometry B Clin Cytom; 2013; 84(4):267-78. PubMed ID: 23554290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multiparametric flow cytometry immunophenotypic scoring system for the diagnosis and prognosis of myelodysplastic syndromes.
    Huang J; Lai P; Zhou M; Weng J; Lu Z; Du X
    Clin Lab; 2012; 58(11-12):1241-51. PubMed ID: 23289195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Bardet V; Wagner-Ballon O; Guy J; Morvan C; Debord C; Trimoreau F; Benayoun E; Chapuis N; Freynet N; Rossi C; Mathis S; Gourin MP; Toma A; Béné MC; Feuillard J; Guérin E; ;
    Haematologica; 2015 Apr; 100(4):472-8. PubMed ID: 25637056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of a single tube 10-color flow cytometry for quantitative and qualitative analysis in myelodysplastic syndrome- a pilot study.
    Chauhan R; Singh J; Sharma C; Dange P; Chopra A; Mahapatra M; Pati H
    Leuk Res; 2021 Aug; 107():106651. PubMed ID: 34218155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
    Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
    Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
    Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
    Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometry in myelodysplastic syndrome: analysis of diagnostic utility using maturation pattern-based and quantitative approaches.
    Chopra A; Pati H; Mahapatra M; Mishra P; Seth T; Kumar S; Singh S; Pandey S; Kumar R
    Ann Hematol; 2012 Sep; 91(9):1351-62. PubMed ID: 22526362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.
    Stetler-Stevenson M; Arthur DC; Jabbour N; Xie XY; Molldrem J; Barrett AJ; Venzon D; Rick ME
    Blood; 2001 Aug; 98(4):979-87. PubMed ID: 11493442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.